nodes	percent_of_prediction	percent_of_DWPC	metapath
Fosamprenavir—Lipase increased—Sorafenib—liver cancer	0.0884	0.0884	CcSEcCtD
Fosamprenavir—Rhabdomyolysis—Sorafenib—liver cancer	0.0294	0.0294	CcSEcCtD
Fosamprenavir—Gastrooesophageal reflux disease—Sorafenib—liver cancer	0.0288	0.0288	CcSEcCtD
Fosamprenavir—Drug hypersensitivity—Epirubicin—liver cancer	0.0238	0.0238	CcSEcCtD
Fosamprenavir—Opportunistic infection—Epirubicin—liver cancer	0.0238	0.0238	CcSEcCtD
Fosamprenavir—Drug hypersensitivity—Doxorubicin—liver cancer	0.022	0.022	CcSEcCtD
Fosamprenavir—Opportunistic infection—Doxorubicin—liver cancer	0.022	0.022	CcSEcCtD
Fosamprenavir—Myositis—Epirubicin—liver cancer	0.0196	0.0196	CcSEcCtD
Fosamprenavir—Myositis—Doxorubicin—liver cancer	0.0181	0.0181	CcSEcCtD
Fosamprenavir—Aspartate aminotransferase increased—Sorafenib—liver cancer	0.017	0.017	CcSEcCtD
Fosamprenavir—Gastritis—Sorafenib—liver cancer	0.0167	0.0167	CcSEcCtD
Fosamprenavir—Alanine aminotransferase increased—Sorafenib—liver cancer	0.0166	0.0166	CcSEcCtD
Fosamprenavir—Neutropenia—Sorafenib—liver cancer	0.0152	0.0152	CcSEcCtD
Fosamprenavir—Stevens-Johnson syndrome—Sorafenib—liver cancer	0.0144	0.0144	CcSEcCtD
Fosamprenavir—Acute coronary syndrome—Sorafenib—liver cancer	0.0143	0.0143	CcSEcCtD
Fosamprenavir—Myocardial infarction—Sorafenib—liver cancer	0.0142	0.0142	CcSEcCtD
Fosamprenavir—Hyperlipidaemia—Epirubicin—liver cancer	0.0133	0.0133	CcSEcCtD
Fosamprenavir—Haemoglobin—Sorafenib—liver cancer	0.0131	0.0131	CcSEcCtD
Fosamprenavir—Haemorrhage—Sorafenib—liver cancer	0.013	0.013	CcSEcCtD
Fosamprenavir—Urinary tract disorder—Sorafenib—liver cancer	0.0129	0.0129	CcSEcCtD
Fosamprenavir—Connective tissue disorder—Sorafenib—liver cancer	0.0128	0.0128	CcSEcCtD
Fosamprenavir—Urethral disorder—Sorafenib—liver cancer	0.0128	0.0128	CcSEcCtD
Fosamprenavir—Erythema multiforme—Sorafenib—liver cancer	0.0123	0.0123	CcSEcCtD
Fosamprenavir—Hyperlipidaemia—Doxorubicin—liver cancer	0.0123	0.0123	CcSEcCtD
Fosamprenavir—Cardiac disorder—Sorafenib—liver cancer	0.0121	0.0121	CcSEcCtD
Fosamprenavir—Immune system disorder—Sorafenib—liver cancer	0.0118	0.0118	CcSEcCtD
Fosamprenavir—Malnutrition—Sorafenib—liver cancer	0.0114	0.0114	CcSEcCtD
Fosamprenavir—Angioedema—Sorafenib—liver cancer	0.0104	0.0104	CcSEcCtD
Fosamprenavir—Inflammation—Epirubicin—liver cancer	0.0099	0.0099	CcSEcCtD
Fosamprenavir—Myalgia—Sorafenib—liver cancer	0.00967	0.00967	CcSEcCtD
Fosamprenavir—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—liver cancer	0.0096	0.0096	CcSEcCtD
Fosamprenavir—Inflammation—Doxorubicin—liver cancer	0.00916	0.00916	CcSEcCtD
Fosamprenavir—Nervous system disorder—Sorafenib—liver cancer	0.00909	0.00909	CcSEcCtD
Fosamprenavir—Skin disorder—Sorafenib—liver cancer	0.009	0.009	CcSEcCtD
Fosamprenavir—Anorexia—Sorafenib—liver cancer	0.00883	0.00883	CcSEcCtD
Fosamprenavir—Musculoskeletal discomfort—Sorafenib—liver cancer	0.00844	0.00844	CcSEcCtD
Fosamprenavir—Decreased appetite—Sorafenib—liver cancer	0.00806	0.00806	CcSEcCtD
Fosamprenavir—Diabetes mellitus—Epirubicin—liver cancer	0.00801	0.00801	CcSEcCtD
Fosamprenavir—Gastrointestinal disorder—Sorafenib—liver cancer	0.008	0.008	CcSEcCtD
Fosamprenavir—Fatigue—Sorafenib—liver cancer	0.00799	0.00799	CcSEcCtD
Fosamprenavir—Gastrointestinal pain—Sorafenib—liver cancer	0.00758	0.00758	CcSEcCtD
Fosamprenavir—Diabetes mellitus—Doxorubicin—liver cancer	0.00741	0.00741	CcSEcCtD
Fosamprenavir—Abdominal pain—Sorafenib—liver cancer	0.00733	0.00733	CcSEcCtD
Fosamprenavir—Body temperature increased—Sorafenib—liver cancer	0.00733	0.00733	CcSEcCtD
Fosamprenavir—Hypersensitivity—Sorafenib—liver cancer	0.00683	0.00683	CcSEcCtD
Fosamprenavir—Asthenia—Sorafenib—liver cancer	0.00665	0.00665	CcSEcCtD
Fosamprenavir—Pruritus—Sorafenib—liver cancer	0.00656	0.00656	CcSEcCtD
Fosamprenavir—Diarrhoea—Sorafenib—liver cancer	0.00634	0.00634	CcSEcCtD
Fosamprenavir—Aspartate aminotransferase increased—Epirubicin—liver cancer	0.00627	0.00627	CcSEcCtD
Fosamprenavir—Gastritis—Epirubicin—liver cancer	0.00617	0.00617	CcSEcCtD
Fosamprenavir—Alanine aminotransferase increased—Epirubicin—liver cancer	0.00615	0.00615	CcSEcCtD
Fosamprenavir—Dizziness—Sorafenib—liver cancer	0.00613	0.00613	CcSEcCtD
Fosamprenavir—Vomiting—Sorafenib—liver cancer	0.00589	0.00589	CcSEcCtD
Fosamprenavir—Rash—Sorafenib—liver cancer	0.00584	0.00584	CcSEcCtD
Fosamprenavir—Dermatitis—Sorafenib—liver cancer	0.00584	0.00584	CcSEcCtD
Fosamprenavir—Aspartate aminotransferase increased—Doxorubicin—liver cancer	0.00581	0.00581	CcSEcCtD
Fosamprenavir—Headache—Sorafenib—liver cancer	0.0058	0.0058	CcSEcCtD
Fosamprenavir—Gastritis—Doxorubicin—liver cancer	0.00571	0.00571	CcSEcCtD
Fosamprenavir—Alanine aminotransferase increased—Doxorubicin—liver cancer	0.00569	0.00569	CcSEcCtD
Fosamprenavir—Neutropenia—Epirubicin—liver cancer	0.00563	0.00563	CcSEcCtD
Fosamprenavir—Nausea—Sorafenib—liver cancer	0.0055	0.0055	CcSEcCtD
Fosamprenavir—Hyperglycaemia—Epirubicin—liver cancer	0.00543	0.00543	CcSEcCtD
Fosamprenavir—Stevens-Johnson syndrome—Epirubicin—liver cancer	0.00532	0.00532	CcSEcCtD
Fosamprenavir—Neutropenia—Doxorubicin—liver cancer	0.00521	0.00521	CcSEcCtD
Fosamprenavir—Hyperglycaemia—Doxorubicin—liver cancer	0.00503	0.00503	CcSEcCtD
Fosamprenavir—Stevens-Johnson syndrome—Doxorubicin—liver cancer	0.00493	0.00493	CcSEcCtD
Fosamprenavir—Haemoglobin—Epirubicin—liver cancer	0.00484	0.00484	CcSEcCtD
Fosamprenavir—Haemorrhage—Epirubicin—liver cancer	0.00482	0.00482	CcSEcCtD
Fosamprenavir—Urinary tract disorder—Epirubicin—liver cancer	0.00476	0.00476	CcSEcCtD
Fosamprenavir—Connective tissue disorder—Epirubicin—liver cancer	0.00474	0.00474	CcSEcCtD
Fosamprenavir—Urethral disorder—Epirubicin—liver cancer	0.00472	0.00472	CcSEcCtD
Fosamprenavir—Erythema multiforme—Epirubicin—liver cancer	0.00456	0.00456	CcSEcCtD
Fosamprenavir—Haemoglobin—Doxorubicin—liver cancer	0.00448	0.00448	CcSEcCtD
Fosamprenavir—Cardiac disorder—Epirubicin—liver cancer	0.00447	0.00447	CcSEcCtD
Fosamprenavir—Haemorrhage—Doxorubicin—liver cancer	0.00446	0.00446	CcSEcCtD
Fosamprenavir—Urinary tract disorder—Doxorubicin—liver cancer	0.0044	0.0044	CcSEcCtD
Fosamprenavir—Connective tissue disorder—Doxorubicin—liver cancer	0.00438	0.00438	CcSEcCtD
Fosamprenavir—Urethral disorder—Doxorubicin—liver cancer	0.00437	0.00437	CcSEcCtD
Fosamprenavir—Immune system disorder—Epirubicin—liver cancer	0.00435	0.00435	CcSEcCtD
Fosamprenavir—Erythema multiforme—Doxorubicin—liver cancer	0.00422	0.00422	CcSEcCtD
Fosamprenavir—Malnutrition—Epirubicin—liver cancer	0.0042	0.0042	CcSEcCtD
Fosamprenavir—Cardiac disorder—Doxorubicin—liver cancer	0.00414	0.00414	CcSEcCtD
Fosamprenavir—Flatulence—Epirubicin—liver cancer	0.00413	0.00413	CcSEcCtD
Fosamprenavir—Immune system disorder—Doxorubicin—liver cancer	0.00403	0.00403	CcSEcCtD
Fosamprenavir—Malnutrition—Doxorubicin—liver cancer	0.00388	0.00388	CcSEcCtD
Fosamprenavir—Flatulence—Doxorubicin—liver cancer	0.00383	0.00383	CcSEcCtD
Fosamprenavir—Myalgia—Epirubicin—liver cancer	0.00357	0.00357	CcSEcCtD
Fosamprenavir—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—liver cancer	0.00355	0.00355	CcSEcCtD
Fosamprenavir—Nervous system disorder—Epirubicin—liver cancer	0.00336	0.00336	CcSEcCtD
Fosamprenavir—Skin disorder—Epirubicin—liver cancer	0.00333	0.00333	CcSEcCtD
Fosamprenavir—Myalgia—Doxorubicin—liver cancer	0.00331	0.00331	CcSEcCtD
Fosamprenavir—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—liver cancer	0.00328	0.00328	CcSEcCtD
Fosamprenavir—Anorexia—Epirubicin—liver cancer	0.00326	0.00326	CcSEcCtD
Fosamprenavir—Musculoskeletal discomfort—Epirubicin—liver cancer	0.00312	0.00312	CcSEcCtD
Fosamprenavir—Nervous system disorder—Doxorubicin—liver cancer	0.00311	0.00311	CcSEcCtD
Fosamprenavir—Skin disorder—Doxorubicin—liver cancer	0.00308	0.00308	CcSEcCtD
Fosamprenavir—Anorexia—Doxorubicin—liver cancer	0.00302	0.00302	CcSEcCtD
Fosamprenavir—Decreased appetite—Epirubicin—liver cancer	0.00298	0.00298	CcSEcCtD
Fosamprenavir—Gastrointestinal disorder—Epirubicin—liver cancer	0.00296	0.00296	CcSEcCtD
Fosamprenavir—Fatigue—Epirubicin—liver cancer	0.00295	0.00295	CcSEcCtD
Fosamprenavir—Musculoskeletal discomfort—Doxorubicin—liver cancer	0.00289	0.00289	CcSEcCtD
Fosamprenavir—Gastrointestinal pain—Epirubicin—liver cancer	0.0028	0.0028	CcSEcCtD
Fosamprenavir—Decreased appetite—Doxorubicin—liver cancer	0.00275	0.00275	CcSEcCtD
Fosamprenavir—Gastrointestinal disorder—Doxorubicin—liver cancer	0.00274	0.00274	CcSEcCtD
Fosamprenavir—Fatigue—Doxorubicin—liver cancer	0.00273	0.00273	CcSEcCtD
Fosamprenavir—Abdominal pain—Epirubicin—liver cancer	0.00271	0.00271	CcSEcCtD
Fosamprenavir—Body temperature increased—Epirubicin—liver cancer	0.00271	0.00271	CcSEcCtD
Fosamprenavir—Gastrointestinal pain—Doxorubicin—liver cancer	0.00259	0.00259	CcSEcCtD
Fosamprenavir—Hypersensitivity—Epirubicin—liver cancer	0.00252	0.00252	CcSEcCtD
Fosamprenavir—Body temperature increased—Doxorubicin—liver cancer	0.0025	0.0025	CcSEcCtD
Fosamprenavir—Abdominal pain—Doxorubicin—liver cancer	0.0025	0.0025	CcSEcCtD
Fosamprenavir—Asthenia—Epirubicin—liver cancer	0.00246	0.00246	CcSEcCtD
Fosamprenavir—Pruritus—Epirubicin—liver cancer	0.00242	0.00242	CcSEcCtD
Fosamprenavir—Diarrhoea—Epirubicin—liver cancer	0.00234	0.00234	CcSEcCtD
Fosamprenavir—Hypersensitivity—Doxorubicin—liver cancer	0.00233	0.00233	CcSEcCtD
Fosamprenavir—Asthenia—Doxorubicin—liver cancer	0.00227	0.00227	CcSEcCtD
Fosamprenavir—Dizziness—Epirubicin—liver cancer	0.00226	0.00226	CcSEcCtD
Fosamprenavir—Pruritus—Doxorubicin—liver cancer	0.00224	0.00224	CcSEcCtD
Fosamprenavir—Vomiting—Epirubicin—liver cancer	0.00218	0.00218	CcSEcCtD
Fosamprenavir—Diarrhoea—Doxorubicin—liver cancer	0.00217	0.00217	CcSEcCtD
Fosamprenavir—Rash—Epirubicin—liver cancer	0.00216	0.00216	CcSEcCtD
Fosamprenavir—Dermatitis—Epirubicin—liver cancer	0.00216	0.00216	CcSEcCtD
Fosamprenavir—Headache—Epirubicin—liver cancer	0.00215	0.00215	CcSEcCtD
Fosamprenavir—Dizziness—Doxorubicin—liver cancer	0.0021	0.0021	CcSEcCtD
Fosamprenavir—Nausea—Epirubicin—liver cancer	0.00203	0.00203	CcSEcCtD
Fosamprenavir—Vomiting—Doxorubicin—liver cancer	0.00201	0.00201	CcSEcCtD
Fosamprenavir—Rash—Doxorubicin—liver cancer	0.002	0.002	CcSEcCtD
Fosamprenavir—Dermatitis—Doxorubicin—liver cancer	0.002	0.002	CcSEcCtD
Fosamprenavir—Headache—Doxorubicin—liver cancer	0.00199	0.00199	CcSEcCtD
Fosamprenavir—Nausea—Doxorubicin—liver cancer	0.00188	0.00188	CcSEcCtD
